RAS Meetings and Videos

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Upcoming Seminars, Workshops, and Conferences

RAS Initiative Session at 2017 AACR Annual Meeting
Sunday, April 2, 2017, 2:45 pm, Washington, D.C.

Videos and Recorded Webcasts

2015

image of Dr. Frank McCormick from the video of him speaking

Dr. Frank McCormick, "Targeting K-Ras Induced Stem-ness"

Dr. Frank McCormick, UCSF, describes recent progress in understanding of connections between KRAS and stem-ness. June 11, 2015, at the National Cancer Institute, Frederick, Maryland.

AACR Annual Meeting 2015

Free videos from the 2015 AACR Annual Meeting

All the scientific presentations from the 2015 Annual Meeting of the American Association for Cancer Research in Philadelphia, USA that are available for viewing without charge may now be found on the AACR web site.

Drug screening targeting KRAS

Drug Screens Targeting KRAS

Dr. Matt Holderfield of the Frederick National Lab describes the development of multiple drug screening platforms targeting KRAS in the NCI RAS Initiative. April 21, 2015 at the AACR Annual Meeting, Philadelphia, USA.

Dr. Michael Stratton of the Welcome Trust Sanger Institute, Cambridge, UK

How Do the Mutations Underlying Cancers Arise?

Dr. Michael Stratton of the Welcome Trust Sanger Institute, Cambridge, UK describes new insights into the mutational processes that drive cancers. (Dr. Stratton's sciencific remarks begin five minutes into the video.) April 19, 2015 at the AACR Annual Meeting, Philadelphia USA.

Susan Bates, M.D. and Frank McCormick, Ph.D.

Demystifying Medicine 2015 - RAS: A Cancer Mechanism and Target

Dr. Susan Bates of the NCI's Developmental Therapeutics Branch and Dr. Frank McCormick, science advisor to the NCI RAS Initiative, describe the impact of RAS mutations on human health, and new information on regulation of RAS signaling. February 10, 2015 at the National Cancer Institute, Bethesda, Maryland

2014

Dr. Mariano Barbacid, "Targeting K-RAS Driven Cancer" Video Graphic

Dr. Mariano Barbacid, "Targeting K-RAS Driven Cancer"

Dr. Mariano Barbacid of the Centro Nacional de Investigaciones Oncologicas in Madrid, Spain describes how engineered mouse models are being used to understand the role of KRAS in human cancers. November 12, 2014, at the Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland

Cyril Benes, Ph.D., "Identification of Drug Response Predictors and Therapeutic Strategies by High-Throughput Cell Line Screening" Video Graphic

Dr. Cyril Benes, "Identification of Drug Response Predictors and Therapeutic Strategies by High-Throughput Cell Line Screening"

Dr. Cyril Benes of Massachusetts General Hospital and Harvard Medical School describes his lab's efforts to correlate genotypes and other molecular data with drug sensitivities in hundreds of cell lines derived from human tumors. October 17, 2014, at the Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland

2014 RAS Symposium Presentations

The following ten presentations were presented at the symposium "Targeting RAS Now for Future Cancer Therapy," held at the University of California, San Francisco (UCSF), June 19 and 20, 2014

Symposium 2014: Targeting RAS Now for Future Cancer Therapy – Introduction

Dr. Frank McCormick, Director of the UCSF Cancer Center and advisor to the RAS Initiative at FNLCR, describes what we do not know about RAS-driven cancers.

Symposium 2014: Targeting Mutant KRAS with Small Molecules

Dr. Kevan Shokat, UCSF, describes how his group developed a small molecule that directly targets a KRAS mutant found in many human cancers.

Symposium 2014: Targeting KRAS Directly and Indirectly

Dr. Stephen W. Fesik, Vanderbilt-Ingram Cancer Center, describes how fragment-based methods can be applied to trying to drug the undruggable.

Symposium 2014: Merlin/NF2 Inhibits RAS Tumorigenesis Through YAP

Dr. James A. Fagin, Memorial Sloan Kettering, describes mechanisms underlying signaling downstream of RAS proteins.

Symposium 2014: Inhibitors of Interactions between BRAF and CRAF in KRAS Cancers

Dr. Deborah Morrison, NCI, describes inhibitors of RAF-RAF dimerization.

Symposium 2014: Finding vulnerabilities in cells dependent on mutant KRAS

Dr. Julian Downward, the Cancer Research UK London Institute, describes interactions between PI3K and KRAS, synthetic lethal screens, and circulating tumor DNA.

Symposium 2014: Limits to Tolerance of Increased RAS Signaling in Cancer

Dr. Kevin Shannon, UCSF, describes how dominant oncogenes, Notch and KRAS, are down-regulated in drug-resistant leukemias.

Symposium 2014: Tumor heterogeneity in cancer drug response, resistance, and relapse

Dr. Erica Jackson, Genentech, describes enrichment of cells with stem cell markers in populations of lung cancer cells.

Symposium 2014: The Role of NF1 Loss in Lung and Pancreatic Cancer

Dr. Eric Collisson, UCSF, describes genomics and patient studies that highlight the role of NF1 loss in human cancers.

Symposium 2014: New targets and tools to attack KRAS cancers

Dr. Frank McCormick, science advisor to the RAS Initiative at FNLCR, describes work in his lab at UCSF to develop new tools and identify new targets relevant to KRAS cancers.

AACR Annual Meeting 2014 Graphic

Dr. Frank McCormick, "New Targets on the RAS Pathway"

Dr. Frank McCormick describes recent experiments to understand KRAS signaling in cancer at the AACR Annual Meeting, April 5, 2014, San Diego, California USA

2013

NCI-Frederick Advisory Committee Meeting (Select “Morning session”)

Dr. Harold Varmus and other scientific leaders discuss the RAS Initiative at the Frederick National Laboratory for Cancer Research. September 24, 2013, National Cancer Institute, Bethesda, Maryland USA

Dr. Channing Der, "Aberrant RAS and Rho Signalling in Cancer: Drugging the Undruggable"

Dr. Channing Der gives a perspective on past and present attempts to drug mutant KRAS. June 21, 2013, National Cancer Institute, Bethesda, Maryland USA

Structural Aspects of RAS GTPases

Dr. Alfred Wittinghofer, "GTP-binding Proteins as Molecular Switches", Part 1

Dr. Alfred Wittinghofer explains how solving the three-dimensional structure of RAS and other G-proteins allowed him to understand the conserved mechanism by which G-proteins can act as switches. June 19, 2011

Dr. Alfred Wittinghofer, "GTP-binding Proteins as Molecular Switches", Part 2

In the second part of Dr. Wittinghofer's talk he explains the link between GTPases and disease. June 19, 2011

  • Updated: March 2, 2017